А. А. Измайлов

1.6k total citations
50 papers, 250 citations indexed

About

А. А. Измайлов is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, А. А. Измайлов has authored 50 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in А. А. Измайлов's work include Renal cell carcinoma treatment (10 papers), MicroRNA in disease regulation (8 papers) and BRCA gene mutations in cancer (7 papers). А. А. Измайлов is often cited by papers focused on Renal cell carcinoma treatment (10 papers), MicroRNA in disease regulation (8 papers) and BRCA gene mutations in cancer (7 papers). А. А. Измайлов collaborates with scholars based in Russia, China and United States. А. А. Измайлов's co-authors include В. Н. Павлов, Ozal Beylerli, Ilgiz Gareev, Shiguang Zhao, Guang Yang, Э. К. Хуснутдинова, I. R. Gilyazova, Yiwei Zhang, Elizaveta Ivanova and Yanchao Liang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

А. А. Измайлов

39 papers receiving 241 citations

Peers

Countries citing papers authored by А. А. Измайлов

Since Specialization

Citations

This map shows the geographic impact of А. А. Измайлов's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by А. А. Измайлов with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites А. А. Измайлов more than expected).

Fields of papers citing papers by А. А. Измайлов

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by А. А. Измайлов. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by А. А. Измайлов. The network helps show where А. А. Измайлов may publish in the future.

Co-authorship network of co-authors of А. А. Измайлов

This figure shows the co-authorship network connecting the top 25 collaborators of А. А. Измайлов. A scholar is included among the top collaborators of А. А. Измайлов based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with А. А. Измайлов. А. А. Измайлов is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mechanisms of Formation of Specific Antitumor Immunity and Resistance to Immune Checkpoint Inhibitors 2024 ·Voprosy Onkologii ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. А. Измайлов, (unknown), (unknown)	1
2	Palbociclib in real clinical practice: Results of a single-center observational study 2024 ·Meditsinskiy sovet = Medical Council ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. А. Измайлов	0
3	Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study 2024 ·SHILAP Revista de lepidopterología ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. А. Измайлов, (unknown)	0
4	Late progression of renal cell carcinoma after 32 years: clinical case 2024 ·Cancer Urology ·(unknown), (unknown), (unknown), (unknown), А. А. Измайлов, B. Yа. Alekseev, С. А. Иванов	0
5	Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors inClinical Practice in the Volga-Ural Region of the Eurasian Continent 2023 ·Current Pharmaceutical Design ·(unknown), А. В. Султанбаев, А. А. Измайлов, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), I. R. Gilyazova	0
6	Predictors of Multiple Primary Malignancies: Literature Review 2023 ·SHILAP Revista de lepidopterología ·А. В. Султанбаев, (unknown), (unknown), А. А. Измайлов, (unknown), (unknown)	0
7	Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study 2022 ·Journal of Modern Oncology ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), А. А. Измайлов, Oleg Lipatov, (unknown), (unknown), (unknown), (unknown)	1
8	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review 2022 ·SHILAP Revista de lepidopterología ·(unknown), А. В. Султанбаев, (unknown), А. А. Измайлов, (unknown), (unknown), (unknown), (unknown)	0
9	Germline mutations as possible biomarkers of immune checkpoint inhibitor therapy efficacy in patients with renal cell carcinoma (mini review) 2022 ·Open Access Repository (Belgorod State National Research University) ·I. R. Gilyazova, (unknown), (unknown), (unknown), А. А. Измайлов, Marina Bermisheva, (unknown), (unknown), (unknown), Е. В. Попова, (unknown), В. Н. Павлов, Э. К. Хуснутдинова	2
10	Study of the exosomal microRNA-126 and microRNA-218 expression profiles in patients with hemorrhagic fever with renal syndrome (HFRS) 2022 ·Open Access Repository (Belgorod State National Research University) ·I. R. Gilyazova, (unknown), (unknown), (unknown), (unknown), А. А. Измайлов, (unknown), Guoqing Wang, Honglan Huang, Jiahui Pan, Tong Shao, Haochen Yao, Wenfang Wang, Э. К. Хуснутдинова	1
11	Peritoneal Carcinomatosis: Current State of the Art and Schools of Thought 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), А. А. Измайлов, (unknown)	2
12	Metastatic renal cell carcinoma, the possibility of targeted therapy. Case. 2021 ·SHILAP Revista de lepidopterología ·(unknown), А. А. Измайлов, А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), (unknown)	0
13	Experience in treating BRCA-associated breast cancer. The BRCA-history of a family 2021 ·SHILAP Revista de lepidopterología ·А. В. Султанбаев, (unknown), (unknown), А. А. Измайлов, (unknown), (unknown), (unknown), (unknown)	1
14	Organization of screening for prostate cancer in carriers of germinal mutations in the BRCA1 / 2 genes 2020 ·European Urology Open Science ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), (unknown), А. А. Измайлов	3
15	Hereditary prostate cancer screening 2020 ·European Urology Open Science ·А. В. Султанбаев, (unknown), (unknown), (unknown), (unknown), А. А. Измайлов, (unknown)	2
16	Spectrum and frequency of BRCA1, BRCA2, CHEK2, PALB2, RAD50 mutations in breast cancer patients in the Republic of Bashkortostan 2020 ·Kazan medical journal ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), I. R. Gilyazova, А. А. Измайлов, А. В. Султанбаев	1
17	Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Oleg Lipatov, А. А. Измайлов, (unknown), (unknown), (unknown), А. В. Султанбаев	2
18	Treatment of erectile dysfunction in patients after kidney transplantation depending on type of vascular anastomosis: results of short-term follow up study 2019 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), А. А. Измайлов, (unknown), В. Н. Павлов	1
19	Comparative analysis of adverse events using different methods of prostate biopsy 2019 ·SHILAP Revista de lepidopterología ·(unknown), A. V. Zyryаnov, А. А. Измайлов, (unknown), (unknown), (unknown)	1
20	ILEOCYSTOPLASTY IN INVASIVE URINARY BLADDER CARCINOMA 2014 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), А. А. Измайлов, (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact